NRXP all time low! 2 X Phase 3 clinical trials!

NASDAQ:NRXP   NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.

52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.

My price target is 16.50

If this is not the time to buy this stock, then when?!


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.